Figure 2
(a) Overall survival of MYCN-amplified vs nonamplified patients, and (b) survival of patients with intermediate (3.00–5.99) vs low MYCN copy numbers.
Figure 2 | Modern Pathology
(a) Overall survival of MYCN-amplified vs nonamplified patients, and (b) survival of patients with intermediate (3.00–5.99) vs low MYCN copy numbers.
